Blue Light Phototherapy

Not Applicable

Completed

• Conditions: Psoriasis Vulgaris; Grover's Disease
• Interventions: Device: Blue light phototherapy

• Registration Number: NCT04343586
• Lead Sponsor: Northwestern University

Brief Summary

This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2020-01-24
• Study First Submitted QC: 2020-04-10
• Study First Posted: 2020-04-13
• Study Start: 2020-09-01
• Primary Completion: 2021-12-20
• Study Completion: 2022-09-22
• Results First Submitted: 2023-01-12
• Status Verified: 2023-02
• Results First Submitted QC: 2023-02-21
• Last Update Submitted: 2023-02-21
• Results First Posted: 2023-03-17
• Last Update Posted: 2023-03-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

1. Patient's aged 18-89 at time of enrollment
2. Previous diagnosis of psoriasis vulgaris or Grover's disease

Read More

Exclusion Criteria

1. All Groups: Subjects who are younger than 18 years of age or older than 90 years of age

2. Patients who have received topical or systemic treatment within the prior 2 weeks of planned phototherapy

3. Patients prescribed any of the following drugs for issues not related to their psoriasis or Grover's disease

   • topical steroids
   • calcineurin inhibitors
   • methotrexate
   • retinoids
   • biologic agents

4. Unable to schedule phototherapy sessions

5. We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Adult treatment arm	Blue light phototherapy	Adults enrolled in the study will receive treatment (blue light phototherapy) on one area of their body affected by psoriasis or Grover's disease. The treatment area (restricted by size of the device) will be compared to untreated areas affected by disease on the same patient.

Primary Outcome Measures

Name	Time	Method
Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment.	Time Frame: 5 weeks	The DLQI is a questionnaire with 10 questions. The maximum score is 30 and minimum is 0. The higher the score, the more quality of life is impaired.
Efficacy of Blue Light Therapy for Patients With Grover's Disease	Time Frame: 5 weeks	Demonstrate preliminary skin efficacy as measured by lesion count

Trial Locations

Locations (1)

Northwestern University Department of Dermatology; 🇺🇸 Chicago, Illinois, United States